Hikma Creating long-term sustainable value With our unique and established capabilities and strategy for growth, we offer a clear proposition to investors. Performance Our latest results See all financial information Revenue ($m) $2,341m Operating profit ($m) $579m 1 2 3 4 Notes Five reasons to invest in Hikma We have a long track record of creating value for our shareholders. By focusing on our strategic priorities and leveraging our strengths, we can build upon our success. Previous 1 Unique and diversified business model Our business is uniquely positioned, with three main business segments. We have a broad and diversified product portfolio and a growing pipeline of new medicines, that are sold in the retail and hospital markets. 2 Strong market position We are the third largest generic injectable manufacturer and a top ten generic company in the US. In MENA, we are one of the largest pharmaceutical companies with very strong brand awareness. Next 1 of 5 Understanding Hikma Find out how our business model, strategy and established capabilities support our clear investment proposition Find out more Annual Report 2020 Find out how we are performing in our Annual Report Find out more Investors calendar View all events Results and presentations PDF H1 2021 interim results press release PDF H1 interim results presentation LINK 2021 interim results recorded presentation LINK 2021 interim results video | CEO - Siggi Olafsson LINK 2021 interim results video | CFO - Khalid Nabilsi M4A 2021 interim results Q&A recording PDF Branded Meet the Management Presentation LINK Branded Meet the Management Recording PDF Injectables Meet the Management Presentation LINK Injectables Meet the Management Recording More reports Regulatory news News feed from the London Stock Exchange's Regulatory News Service. View all regulatory news Download our Corporate Factsheet PDF Corporate factsheet Share price Up-to-date information including full share price details plus investor tools. Investor tools Share graph Share series Investment calculator Share price look-up Analyst coverage Analyst estimates Corporate governance Information on the high standards of governance we’re committed to, our governance structure, Board, key committees, and remuneration policy. Investor Relations Hikma Pharmaceuticals PLC 1 New Burlington Place, London W1S 2HR Tel: +44(0) 20 7399 2760 Fax: +44(0) 20 7399 2761 Email: investors@hikma.uk.com Investors Back to top Useful links About Products Investors News Careers Contact Worldwide Leadership Stay in touch Subscribe to our newsletter Follow us instagram Created with Sketch. © Hikma Pharmaceuticals PLC 2021 Terms of use Cookie policy Disclaimer Privacy policy Community guidelines Our website uses cookies to improve your experience. Some of the cookies we use are essential for parts of our website to operate. By using our website without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.